Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03599362
Title Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

pancreatic cancer

Therapies

Cabiralizumab + Nivolumab

Age Groups:
Covered Countries USA


No variant requirements are available.